OOTR Studies

Many clinical trials about cancer treatments have been carried out since OOTR formed.

Dr. Louis Chow and Dr. Masakazu Toi have started studying new and useful treatments according to different cancer types. They tried to combine neoadjuvant chemotherapy, or hormone therapy with other anti-cancer drugs. Some of these results have been published in medical journals, in which Translational Research in Asia has taken one step forward.

In recent years, OOTR has carried out many clinical trials research in Asia studying the efficacies and side-effects of new adjuvant chemotherapy drugs; signal changes in cells were also studied using tumour specimens. Many research centres from China, Hong Kong, Japan, Korea, and Taiwan have already started the research, and the results will be announced at international conferences and journals in the near future.

Clinical Trials Open to Accruals include:

N001 / FEC-DOC-CXB-A3

Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients with Invasive Breast Cancer

N003

Randomized Trial of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) 

N006  

A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients after Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy